SCHEMBL29852437

SCHEMBL29852437

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C(F)F)oc2c(C3CC3)cc(-c3cccc(CN)c3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 5/20 0.39
MTNR1A P48039 2/20 0.36
MTNR1B P49286 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PLG P00747 2/20 0.34
PLAU P00749 2/20 0.34
F11 P03951 2/20 0.34
KLKB1 P03952 2/20 0.34
F7 P08709 1/20 0.34
TPSB2 P20231 1/20 0.34
SYK P43405 1/20 0.32
FFAR1 O14842 1/20 0.31
PTGER4 P35408 1/20 0.31
DPP4 P27487 2/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
SLC26A3 P40879 1/20 0.31
PLA2G2A P14555 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218549 1.00 CFD (0.39) CFDMTNR1AMTNR1BKDM4EMEN1
SCHEMBL23218114 0.92 CFD (0.41) CFDMTNR1AMTNR1BKDM4EMEN1
SCHEMBL29852472 0.92 CFD (0.41) CFDMTNR1AMTNR1BKDM4EMEN1
SCHEMBL29591094 0.92 CFD (0.43) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL23218667 0.92 CFD (0.43) CFDMTNR1AMTNR1BPLGPLAU
SCHEMBL23218176 0.88 CFD (0.36) CFDMTNR1AMTNR1BKDM4EMEN1
SCHEMBL29853028 0.88 CFD (0.36) CFDMTNR1AMTNR1BKDM4EMEN1
SCHEMBL23218602 0.86 CFD (0.41) CFDMTNR1AMTNR1BKDM4EMEN1
SCHEMBL29852539 0.86 CFD (0.41) CFDMTNR1AMTNR1BKDM4EMEN1
SCHEMBL23229012 0.85 CFD (0.36) CFDMTNR1AMTNR1BPLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2025-06-12 US disclosed
WO-2025090514-A1 COVALENT SARM1 INHIBITORS NURA BIO, INC. (US) 2025-05-01 WO disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION KMT5A, KMT5B, KMT5C CFD 4621/4885MTNR1A 944/4885MTNR1B 754/4885
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 CFD 3529/4885MTNR1A 3725/4885MTNR1B 3252/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885MTNR1A 3930/4885MTNR1B 3580/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885MTNR1A 3848/4885MTNR1B 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.